MC
HUMA icon

Miramontes Capital’s Humacyte HUMA Stock Holding History

Miramontes Capital’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.8K Buy
+108,695
New +$101K 0.03% 140

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Miramontes Capital's HUMA Position: Q2 2026 in Review

Miramontes Capital opened a new position in Humacyte (HUMA) in Q2 2026: 108,695 shares worth $84.8K. The stake represents 0.03% of the portfolio and ranks #140 among its holdings.

164 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Miramontes Capital held 108,695 shares of Humacyte worth $84.8K as of Q2 2026.
  • Humacyte was a new Miramontes Capital position in Q2 2026.
  • Humacyte made up 0.03% of Miramontes Capital's portfolio in Q2 2026, its #140 holding.
  • 164 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Miramontes Capital's 13F filing for Q2 2026, filed 9 Sep 2026.